Patents by Inventor Rajesh Devraj

Rajesh Devraj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS
    Publication number: 20220008405
    Abstract: The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 13, 2022
    Inventors: Todd BOSANAC, Rajesh DEVRAJ, Thomas ENGBER, Robert Owen HUGHES, Raul Eduardo KRAUSS
  • Heteroaryl inhibitors of PAD4
    Patent number: 11198681
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: December 14, 2021
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye, Philip A. Woods
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20210299115
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: May 12, 2021
    Publication date: September 30, 2021
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • INHIBITORS OF SARM1
    Publication number: 20210261540
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Inventors: Robert Owen Hughes, Rajesh Devraj, Todd Bosanac, Richard Andrew Jarjes-Pike, Andrew Simon Brearley, Jonathan Bentley
  • INHIBITORS OF SARM1
    Publication number: 20210261537
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARMI and/or treating and/or preventing axonal degeneration. Provided SARMI inhibitors reduce or inhibit binding of NAD+ by SARMI and SARMI inhibitors bind to SARMI within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARMI).
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Inventors: Robert Owen Hughes, Rajesh Devraj, Todd Bosanac, Richard Andrew Jarjes-Pike, Andrew Simon Brearley, Jonathan Bentley
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20210188810
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 24, 2021
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye
  • Heteroaryl inhibitors of PAD4
    Patent number: 11026937
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: June 8, 2021
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Covalent inhibitors of PAD4
    Patent number: 10703741
    Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 7, 2020
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristina Lecci, Heather Tye
  • INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF
    Publication number: 20200129493
    Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 30, 2020
    Applicants: Washington University, Disarm Therapeutics, Inc.
    Inventors: Jeffrey MILBRANDT, Kow ESSUMAN, Yo SASAKI, Aaron DIANTONIO, Xianrong MAO, Rajesh DEVRAJ, Raul Eduardo KRAUSS, Robert Owen HUGHES
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20190358216
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: September 11, 2017
    Publication date: November 28, 2019
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • COVALENT INHIBITORS OF PAD4
    Publication number: 20190276432
    Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: July 27, 2017
    Publication date: September 12, 2019
    Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristine Lecci, Heather Tye
  • Bicyclic inhibitors of PAD4
    Patent number: 9963448
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 8, 2018
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
  • Aza-benzimidazole inhibitors of PAD4
    Patent number: 9765093
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: September 19, 2017
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Laura Gleave, Adrian Kotey, Thomas Krulle, Cristina Lecci, Heather Tye, Ian Wigginton
  • AZA-BENZIMIDAZOLE INHIBITORS OF PAD4
    Publication number: 20170166592
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 15, 2017
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Laura Gleave, Adrian Kotey, Thomas Krulle, Cristina Lecci, Heather Tye, Ian Wigginton
  • BICYCLIC INHIBITORS OF PAD4
    Publication number: 20170166565
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 15, 2017
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
  • PYRIDINE DERIVATIVES
    Publication number: 20170073339
    Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Inventors: Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
  • Pyridine derivatives
    Patent number: 9533981
    Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: January 3, 2017
    Assignee: Asana BioSciences, LLC
    Inventors: Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
  • Pyridine Derivatives
    Publication number: 20160340310
    Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
    Type: Application
    Filed: November 13, 2013
    Publication date: November 24, 2016
    Inventors: Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
  • Pyridine derivatives
    Patent number: 9371316
    Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: June 21, 2016
    Assignee: Asana Biosciences, LLC
    Inventors: Roger Astbury Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
  • Pyridine derivatives
    Patent number: 9266873
    Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: February 23, 2016
    Assignee: Asana Biosciences, LLC
    Inventors: Roger Astbury Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj